ATE413400T1 - Cgrp-rezeptorantagonisten - Google Patents

Cgrp-rezeptorantagonisten

Info

Publication number
ATE413400T1
ATE413400T1 AT04749887T AT04749887T ATE413400T1 AT E413400 T1 ATE413400 T1 AT E413400T1 AT 04749887 T AT04749887 T AT 04749887T AT 04749887 T AT04749887 T AT 04749887T AT E413400 T1 ATE413400 T1 AT E413400T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
cgrp receptor
cgrp
antagonists
receptor
Prior art date
Application number
AT04749887T
Other languages
English (en)
Inventor
Christopher Burgey
Zhengwu Deng
Diem Nguyen
Daniel Paone
Anthony Shaw
Theresa WILLIAMS
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE413400T1 publication Critical patent/ATE413400T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04749887T 2003-04-15 2004-04-09 Cgrp-rezeptorantagonisten ATE413400T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46308903P 2003-04-15 2003-04-15
US51035203P 2003-10-10 2003-10-10

Publications (1)

Publication Number Publication Date
ATE413400T1 true ATE413400T1 (de) 2008-11-15

Family

ID=33303112

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749887T ATE413400T1 (de) 2003-04-15 2004-04-09 Cgrp-rezeptorantagonisten

Country Status (32)

Country Link
US (6) US6953790B2 (de)
EP (2) EP2039694B1 (de)
JP (1) JP3967766B2 (de)
KR (1) KR100769030B1 (de)
CN (1) CN100384843C (de)
AR (1) AR045887A1 (de)
AT (1) ATE413400T1 (de)
AU (1) AU2004230926B2 (de)
BR (1) BRPI0409601A (de)
CA (1) CA2522220C (de)
CL (1) CL2004000788A1 (de)
CO (1) CO5640130A2 (de)
CY (1) CY1108714T1 (de)
DE (1) DE602004017608D1 (de)
DK (1) DK1638969T3 (de)
EC (1) ECSP056097A (de)
ES (1) ES2314417T3 (de)
HR (1) HRP20080666T3 (de)
IS (1) IS2759B (de)
JO (1) JO2355B1 (de)
MA (1) MA27728A1 (de)
MX (1) MXPA05011166A (de)
NO (1) NO327655B1 (de)
NZ (1) NZ543357A (de)
PE (1) PE20050020A1 (de)
PL (1) PL1638969T3 (de)
PT (1) PT1638969E (de)
RU (1) RU2308458C2 (de)
SI (1) SI1638969T1 (de)
TW (1) TWI314931B (de)
UA (1) UA82877C2 (de)
WO (2) WO2004092168A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
BRPI0311812B8 (pt) * 2002-06-05 2021-05-25 Bristol Myers Squibb Co antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
EP1615914B1 (de) * 2003-04-15 2010-05-05 Merck Sharp & Dohme Corp. Cgrp-rezeptorantagonisten
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
EP1641781B1 (de) * 2003-06-26 2013-03-06 Merck Sharp & Dohme Corp. Benzodiazepin-CGRP-Rezeptor-Antagonisten
ATE461196T1 (de) * 2003-06-26 2010-04-15 Merck Sharp & Dohme Benzodiazepin-cgrp-rezeptor-antagonisten
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
US7491713B2 (en) * 2004-01-29 2009-02-17 Merck + Co., Inc. CGRP receptor antagonists
JP2007526255A (ja) * 2004-02-23 2007-09-13 トラスティーズ オブ タフツ カレッジ コンフォメーション固定ペプチド模倣物阻害剤としてのラクタム類
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
CN101072771B (zh) * 2004-10-07 2010-09-29 默沙东公司 Cgrp受体拮抗剂
CA2583534A1 (en) 2004-10-14 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
AU2005299852B2 (en) 2004-10-22 2011-08-04 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB2423085C (en) * 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
GB2467060B (en) * 2005-02-11 2010-09-01 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
JP2008533147A (ja) * 2005-03-14 2008-08-21 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
RS20080200A (sr) 2005-11-14 2009-07-15 Rinat Neuroscience Corp., Antagonistička antitela usmerena protiv kalcitonina, peptida povezanog sa genom, i postupak njihovog korišćenja
CN100371327C (zh) * 2005-11-17 2008-02-27 江苏工业学院 2-氨基-6-烷氧基-3-硝基吡啶的一步合成法
EP1954135B1 (de) * 2005-11-18 2012-10-10 Merck Sharp & Dohme Corp. Spirolactam-aryl cgrp-rezeptor-antagonisten
US20100286122A1 (en) * 2006-04-10 2010-11-11 Kevin Belyk CGRP Antagonist Salt
DE602007002182D1 (de) 2006-04-10 2009-10-08 Merck & Co Inc Verfahren zur herstellung von cgrp-antagonisten
AU2007238894A1 (en) * 2006-04-10 2007-10-25 Merck Sharp & Dohme Corp. Process for the preparation of pyridine heterocycle CGRP antagonist intermediate
CA2647683A1 (en) * 2006-04-10 2007-10-25 Merck & Co., Inc. Process for the preparation of caprolactam cgrp antagonist intermediate
US7470679B2 (en) 2006-05-02 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7470680B2 (en) * 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
GEP20115140B (en) * 2006-05-09 2011-01-10 Merck Sharp And Dome Corp Substituted spirocyclic cgrp receptor antagonists
US7834000B2 (en) * 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
NZ574097A (en) * 2006-06-13 2012-01-12 Vertex Pharma Cgrp receptor antagonists
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
HUE026571T2 (hu) * 2006-08-02 2016-06-28 Cytokinetics Inc Adott kémiai anyagok, készítmények és imidazopiridineket magukba foglaló eljárások
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
CA2662748A1 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
CN101679366B (zh) 2007-05-23 2013-08-07 默沙东公司 吡啶基哌啶食欲素受体拮抗剂
GB0712392D0 (en) * 2007-06-26 2007-08-01 Glaxo Group Ltd Novel compounds
US20090075977A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk0974
EP2249833B1 (de) * 2008-02-05 2012-10-17 Merck Sharp & Dohme Corp. Prodrugs von cgrp-rezeptorantagonisten
JP2011512410A (ja) * 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンｃｇｒｐ受容体アンタゴニスト
US8293239B2 (en) 2008-03-04 2012-10-23 Pfizer Limited Methods of treating chronic pain
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US20100009967A1 (en) * 2008-06-30 2010-01-14 Majid Mahjour Solid dosage formulations of telcagepant potassium
EP2348846B1 (de) 2008-10-21 2013-08-28 Merck Sharp & Dohme Corp. Disubstituierte azepanorexin-rezeptorantagonisten
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
CA2771186C (en) 2009-08-28 2018-01-02 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
TWI522355B (zh) 2010-11-12 2016-02-21 默沙東藥廠 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
US20140005214A1 (en) * 2011-03-18 2014-01-02 Ian M. Bell Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
JP6189832B2 (ja) 2011-05-20 2017-08-30 アルダーバイオ・ホールディングズ・エルエルシー 慢性および急性の下痢を治療または予防するための抗ｃｇｒｐ若しくは抗ｃｇｒｐ−ｒの抗体または抗体断片の使用
RS58621B1 (sr) 2011-05-20 2019-05-31 Alderbio Holdings Llc Anti-cgrp kompozicije i njihova upotreba
NZ732970A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
MX352171B (es) 2012-02-27 2017-11-13 Bristol Myers Squibb Co Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato.
CN104203925A (zh) 2012-03-29 2014-12-10 拜耳知识产权有限责任公司 5-氨基嘧啶衍生物及其用于防治不希望的植物生长的用途
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR102274964B1 (ko) 2014-03-21 2021-07-09 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
GB201417707D0 (en) 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
FI3515937T3 (fi) 2016-09-23 2026-02-11 Teva Pharmaceuticals Int Gmbh Refraktaarisen migreenin hoito
EP3366286A1 (de) 2017-02-22 2018-08-29 Johannes Keller Verbindungen zur behandlung von sepsis
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
CN111683937A (zh) 2018-01-19 2020-09-18 爱杜西亚药品有限公司 C5a受体调节剂
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN108892635A (zh) * 2018-09-07 2018-11-27 江苏工程职业技术学院 一种西沙必利关键中间体的制备方法
PH12021551478A1 (en) 2019-01-08 2022-05-02 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies
GB201908430D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
GB201908420D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
AU2021319090A1 (en) 2020-07-29 2023-03-02 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
MX2023010115A (es) 2021-03-02 2023-11-09 Cgrp Diagnostics Gmbh Tratamiento y/o reducción de la aparición de la migraña.
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
MX2024003952A (es) 2021-09-27 2024-05-27 Allergan Pharmaceuticals Int Ltd Combinación que comprende atogepant para tratar la migraña.
CN116903616B (zh) * 2023-07-17 2025-08-01 江西同和药业股份有限公司 一种瑞美吉泮中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE19503160A1 (de) * 1995-02-01 1996-08-08 Bayer Ag Verwendung von Phenylcyclohexylcarbonsäureamiden
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
JP2002525371A (ja) * 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
DK1120415T3 (da) 1998-09-30 2003-11-03 Taisho Pharmaceutical Co Ltd Substituerede isoxazolylthiophenforbindelser
BRPI0311812B8 (pt) * 2002-06-05 2021-05-25 Bristol Myers Squibb Co antagonistas de receptor de peptídeo relacionado com o gene de calcitonina, composição farmacêutica e seu uso
EP1615914B1 (de) * 2003-04-15 2010-05-05 Merck Sharp & Dohme Corp. Cgrp-rezeptorantagonisten

Also Published As

Publication number Publication date
KR100769030B1 (ko) 2007-10-22
DE602004017608D1 (de) 2008-12-18
AR045887A1 (es) 2005-11-16
MXPA05011166A (es) 2005-12-14
HRP20080666T3 (en) 2009-01-31
AU2004230926B2 (en) 2008-07-17
MA27728A1 (fr) 2006-01-02
US7534784B2 (en) 2009-05-19
DK1638969T3 (da) 2009-01-26
US7235545B2 (en) 2007-06-26
PT1638969E (pt) 2009-01-16
WO2004092166A2 (en) 2004-10-28
PE20050020A1 (es) 2005-02-18
CY1108714T1 (el) 2014-04-09
NZ543357A (en) 2008-08-29
US7893052B2 (en) 2011-02-22
AU2004230926A1 (en) 2004-10-28
RU2005135440A (ru) 2006-03-20
RU2308458C2 (ru) 2007-10-20
SI1638969T1 (sl) 2009-02-28
EP1638969B1 (de) 2008-11-05
US20040229861A1 (en) 2004-11-18
CA2522220C (en) 2009-06-23
CA2522220A1 (en) 2004-10-28
EP2039694A1 (de) 2009-03-25
US20050256098A1 (en) 2005-11-17
KR20050121734A (ko) 2005-12-27
UA82877C2 (en) 2008-05-26
ECSP056097A (es) 2006-03-01
WO2004092168A1 (en) 2004-10-28
HK1090922A1 (en) 2007-01-05
TWI314931B (en) 2009-09-21
EP2039694B1 (de) 2014-03-26
JO2355B1 (en) 2006-12-12
CN1802376A (zh) 2006-07-12
IS8055A (is) 2005-09-29
CO5640130A2 (es) 2006-05-31
US7772224B2 (en) 2010-08-10
PL1638969T3 (pl) 2009-04-30
WO2004092166A3 (en) 2005-01-20
NO327655B1 (no) 2009-09-07
US20100298303A1 (en) 2010-11-25
BRPI0409601A (pt) 2006-04-18
US7452903B2 (en) 2008-11-18
JP3967766B2 (ja) 2007-08-29
IS2759B (is) 2011-10-15
US20080280857A1 (en) 2008-11-13
TW200505903A (en) 2005-02-16
US20070225272A1 (en) 2007-09-27
CL2004000788A1 (es) 2005-02-25
NO20055375L (no) 2005-11-14
ES2314417T3 (es) 2009-03-16
US20090192139A1 (en) 2009-07-30
US6953790B2 (en) 2005-10-11
EP1638969A2 (de) 2006-03-29
JP2006523697A (ja) 2006-10-19
CN100384843C (zh) 2008-04-30

Similar Documents

Publication Publication Date Title
ATE413400T1 (de) Cgrp-rezeptorantagonisten
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
DK1951660T3 (da) Histamin-3-receptorantagonister
ATE494285T1 (de) Muscarinische acetylcholin-rezeptor-antagonisten
NO20051871D0 (no) Opioid reseptorantagonister
CY2015029I2 (el) Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης
DK1720859T3 (da) Chemokinreceptorantagonister
PT2570128T (pt) Antagonistas do receptor muscarínico de acetilcolina
EP1641781A4 (de) Benzodiazepin-cgrp-rezeptor-antagonisten
EP1765805A4 (de) Cgrp-rezeptorantagonisten
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
DE60216229D1 (de) Il-8-rezeptorantagonisten
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
EP1799672A4 (de) Cgrp-rezeptorantagonisten
FI20060188L (fi) Modifioidut IL-4-muteiinin reseptorin antagonistit
NO20033223L (no) Histamin-reseptor antagonister
ATE528291T1 (de) Cyclopropylderivate als nk3 rezeptor-antagonisten
ATE320254T1 (de) Crf receptor antagonisten
EP1534736A4 (de) Antagonisten des nogo-rezeptors
DE602004018527D1 (de) Furanderivate als ep4-rezeptorantagonisten
DE602005007719D1 (de) Antagonisten des opioidrezeptors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1638969

Country of ref document: EP

EEFA Change of the company name